The synthesis and evaluation of RGD?conjugated chitosan gel as daily supplement for body weight control
Journal
Materials
Journal Volume
14
Journal Issue
16
Date Issued
2021
Author(s)
Abstract
(1) Background: Obesity is one of the most widespread chronic diseases and increases the risk of several other chronic diseases, especially type 2 diabetes. (2) Methods: Endobarrier is a new medical device what is worn in the small intestines for the treatment of type 2 diabetes and obesity. However, given the invasive and other adverse effects of the Endobarrier, we propose the use of RGD peptide conjugated with chitosan (RC) as an alternative. (3) Results: The FTIR and NMR spectrum showed RGD peptide was successfully conjugated on chitosan and RGD?CT is retained in the small intestine even after digestion. In vitro of wst-1 and live and dead staining studies show that the RGD?CT gel is highly biocompatible and non-toxic. Rats treated with the RGD?CT gel for a short term showed significant decrease change more than 30% in body weight, while the blood and hematic biometrics were within normal values. (4) Conclusions: The RGD?CT gel is safe, suitable for the short-term, reducing visceral fat rate health food to control weight. In the future, it is expected to develop a safe, long-term effective, flexibility of use and low-side-effect anti-obesity therapy in the era of precision medicine by further modification. ? 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Subjects
Chitosan
Highly biocompatibility
Obesity
RGD
Type 2 diabetes
Anthropometry
Biocompatibility
Diseases
Nuclear magnetic resonance spectroscopy
Nutrition
Peptides
Weight control
Adverse effect
Chitosan gel
Chronic disease
FTIR and NMR spectra
Medical Devices
Small intestine
Type-2 diabetes
Visceral fat
SDGs
Type
journal article